Age Related Macular Degeneration, Diabetic Macular Edema
Conditions
Keywords
ocular perfusion, laser speckle flowgraphy, anti-VEGF
Brief summary
This prospective study will include patients with neovascular age-related macular degeneration or diabetic macular edema, scheduled for intravitreal aflibercept. Ocular perfusion will be measured by Laser Speckle Flowgraphy (LSFG). The parameter Mean Blur Rate (MBR) reflects erythrocyte flow velocity and serves as an indirect marker of perfusion. MBR will be measured at the optic nerve head (ONH). The devices software can analyze MBR in areas of major retinal vessels (MV) and in microperfusion areas (MT) separately. Measurements will be conducted on the day of the planned intravitreal injection and one and four weeks post-injection.
Interventions
After instillation of topical anesthesia (0.4% oxybuprocaine hydrochloride and lidocain; own production), sterilization of the eyelid (Betaisodona solution 11% povidone-iodine, Mundipharma, Limburg, Germany), and instillation of 1.25% povidone-iodine drops, 2.0 mg/0.05 mL of aflibercept (Eylea) will be injected into the vitreous cavity through a standard pars plana approach (3.5 mm posterior to the limbus) under sterile conditions.
DEVICELaser speckle flowgraphy
The RetFlow consists of a fundus camera equipped with a diode laser at a wavelength of 830 nm and a digital charge-coupled device camera (750 x 360 pixels). A total of 118 images are acquired at a rate of 30 frames per second over a 4-second measurement period. The main output parameter of LSFG, mean blur rate (MBR), is calculated from the pattern of speckle contrast produced by the interference of a laser scattered by blood cells moving in the ocular fundus. MBR was calculated for the total ONH area, defined by a ellipsoid region of interest (ROI). By using the on-board software, the MBR will be calculated in the large vessels within the ONH (ONH-MV, mean MBR of vascular area) and the tissue area containing the microvasculature (ONH-MT, mean MBR of tissue area)
Sponsors
Augenabteilung Allgemeines Krankenhaus Linz
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* age \> 50 years, * patients scheduled for an intravitreal injections with Aflibercept for treatment of DME or AMD.
Exclusion criteria
* ocular surgery (including intravitreal injection) during the 3 months preceding the study * Ametropia \> 6 Dpt * any relevant ophthalmic diseases/conditions that could interfere with LSFG measurements (e.g. glaucoma, optic nerve head drusen, tilted disc, etc.).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean blur rate in retinal vessels (MV) | Baseline; Week 1; Week 4; | With the onboard software, MBR can be calculated in the large vessels within the ONH (ONH-MV, mean MBR of vascular area) |
Countries
Austria
Outcome results
None listed